
HD is an autosomal dominant genetic disorder with a global prevalence of approximately 2.7/100,000 and an incidence rate of about 0.38/100,000 annually. The prevalence is around 5.7/100,000 in Europe, North America, and Australia, and about 0.4/100,000 in Asia. The causative gene for HD is the huntingtin gene (HTT), which encodes a large protein with over 3,000 amino acids. An abnormal expansion of CAG trinucleotide repeats in the first exon of HTT leads to misfolding of the huntingtin protein (mHTT). This mutated protein accumulates in the brain, ultimately causing neurological dysfunction and degeneration. Targeting the suppression of mHTT expression may be key to treating Huntington’s disease.
On May 17, 2024, Professors Xiaojiang Li and Su Yang from Jinan University published their latest research findings in the journal Science Advances. Their study reported previously unidentified pathogenic mechanisms of HTT and discovered a primate-specific E3 ubiquitin ligase, TRIM37. TRIM37 promotes the ubiquitination and degradation of mutant HTT (mHTT) and regulates its aggregation in the brains of mice and monkeys. Therefore, TRIM37 protein can be considered a potential therapeutic target for Huntington’s disease by modulating mHTT expression. PackGene provided AAV packaging services for this study.

https://pubmed.ncbi.nlm.nih.gov/38758800/
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
More Articles
AAV Immunogenicity: Challenges, Developments, and Innovations
Adeno-associated viruses (AAVs) have emerged as one of the most promising vectors for gene therapy due to their ability to efficiently deliver therapeutic genes to a wide range of tissues, their relatively low immunogenicity compared to other viral vectors, and their...
Riding Momentum in the DMD Space: A New Wave of Progress
Recently, topline results from Part 2 of Sarepta Therapeutics’ EMBARK trial showed significant improvements in motor function among Duchenne muscular dystrophy (DMD) patients who switched from placebo to Elevidys. These findings reinforce the potential of Elevidys to...
AAV-Cas13d for Multiplexed Immunosuppressive Gene Inhibition in Cancer Therapy
Feifei Zhang et al. recently published a research article in Nature Biotechnology titled "Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy." This paper describes a novel multiplexed, universal combinatorial...
The Hidden Threat to AAV Purity: Uncovering Ferritin Contamination
Adeno-associated virus (AAV), valued for its low immunogenicity, broad tropism, and long-lasting in vivo gene expression, has emerged as the leading vector for gene therapy delivery. For AAV vectors intended for clinical use, the FDA requires stringent quality control...
Related Services

AAV Packaging Services
READ MORE

AAV Packaging Service (NHP)
READ MORE

AAV Packaging Service (HT)
READ MORE